Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US.
The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and will evaluate the investigational vaccine for safety and its ability to elicit an immune response.
“An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus. With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal,” said Acting NIAID Director Hugh Auchincloss.
The vaccine candidate under investigation, FluMos-v2, was designed by researchers at NIAID’s Vaccine Research Center (VRC). It is an adaptation of an earlier universal flu vaccine candidate, FluMos-v1, which began first-in-human testing in 2021 and is still undergoing trials.
FluMos-v2 is designed to induce antibodies against many different influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein in repeating patterns on self-assembling nanoparticle scaffolds. The vaccine produced robust antibody responses in animal testing.
While the FluMos-v1 vaccine candidate displays HA from four strains of influenza virus, FluMos-v2 displays HA from six: four influenza A viruses and two influenza B viruses. The researchers anticipate that this will further broaden vaccine recipients’ immunity, providing protection against a wider variety of influenza viruses.
The new clinical trial is expected to enrol 24 healthy volunteers, aged 18-50 years, who will receive two intramuscular injections of the FluMos-v2 vaccine candidate. At first, participants will be enrolled in the lower dose group (60mcg per vaccination). If no safety concerns are identified, enrolment will begin in the higher dose (180 mcg per vaccination) group.